GovWire

Official Statistics: Early access to medicines scheme applications: pending, refused, granted

Medicines Healthcare Products Regulatory Agency

November 8
17:27 2023

Scientific opinion statistics

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

PIM designation statistics

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

These tables show the number of applications made to the early access to medicines scheme for the promising innovative medicine (PIM) designation and the scientific opinion.

The tables also show the number of applications that have been granted and refused as well as the number of pending applications.

The tables will be updated regularly.

Published 27 May 2015
Last updated 8 November 2023 +show all updates
  1. Updated the 'scientific opinion' and 'PIM designation' statistics

  2. Scientific opinion statistics file updated.

  3. PIM designations and scientific opinion statistics updated.

  4. Updated page with new statistics information to April 2022

  5. Updated documents 'PIM designation statistics' and 'Scientific opinion statistics' with the latest statistics.

  6. Updates EAM stats

  7. Updates PIM stats

  8. Updated the PIM designation and Scientific opinion statistics

  9. Updated early access to medicine scheme scientific opinions

  10. Published updated statistics of P

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: